Drug Profile
AG 2009
Latest Information Update: 21 Oct 1997
Price :
$50
*
At a glance
- Originator Agouron Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Aminoimidazolecarboxamide ribonucleotide formyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Oct 1997 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 24 Oct 1996 Preclinical development for Cancer in USA (Unknown route)